Cagrilintide
CGL20
Lyophilized peptide for use under a licensed healthcare provider. Choose single ampule/vial or box of 10. Sourced via Ares Technology Limited (Hong Kong) / Healthtide Biotech manufacturing list dated 7 October 2026. Specification: 20 mg × 10 vials.
- • Prescription / clinician-supervised pathway
- • Same LIRAVEXIN cart and checkout as pen packages
- • Not medical advice — individual suitability is determined by your clinician
Clinical reference (clinician-supervised)
Cagrilintide mimics amylin’s satiety and gastric-emptying effects. Late-stage obesity programs (including coadministration with semaglutide) have reported clinically meaningful weight loss. It is not a routine FDA-labeled monotherapy product for consumer use; clinic interest is in supervised metabolic pathways and combination protocols under research or special-access frameworks where lawful.
REDEFINE / CagriSema programs commonly target about 2.4 mg cagrilintide subcutaneously once weekly after a multi-week escalation (on the order of ~16 weeks to maintenance in published overviews). Standalone historical dose-finding used lower weekly mg ranges. No single universal approved label dose for all regions.
Once weekly SC in major trials.
Subcutaneous.
Typical clinical / literature ranges under clinician supervision — not a prescription and not a DIY dosing guide. Individual dosing is determined solely by the treating clinician.
Liravexin USD for this pack (wholesale comparison · source × 3). Item is added to your shared cart for checkout coordination with your clinician pathway.
Or continue to checkout →